Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Interpace Diagnostics Group ( (IDXG) ) has issued an update.
On December 3, 2025, Interpace Biosciences announced the early repayment of its term loan facility with BroadOak Capital Partners, ahead of its maturity date. This move eliminates interest expenses and enhances operational flexibility, allowing the company to focus on commercial growth and strengthen its balance sheet, as it continues to deliver record testing volumes and revenue for its thyroid tests.
The most recent analyst rating on (IDXG) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Interpace Diagnostics Group stock, see the IDXG Stock Forecast page.
Spark’s Take on IDXG Stock
According to Spark, TipRanks’ AI Analyst, IDXG is a Neutral.
Interpace Diagnostics Group’s stock score is primarily driven by its strong valuation, indicating potential undervaluation. Financial performance shows improvement but is hindered by negative equity. Technical indicators suggest weak momentum, which could impact short-term performance.
To see Spark’s full report on IDXG stock, click here.
More about Interpace Diagnostics Group
Interpace Biosciences is an emerging leader in personalized medicine, offering services from early diagnosis to targeted therapeutic applications. It provides molecular diagnostic tests and bioinformatics services for cancer risk evaluation, with products like ThyGeNEXT and ThyraMIRv2 for thyroid cancer diagnosis.
Average Trading Volume: 8,316
Technical Sentiment Signal: Strong Sell
Current Market Cap: $3.8M
For a thorough assessment of IDXG stock, go to TipRanks’ Stock Analysis page.